c-Met targeting in advanced gastric cancer: An open challenge
- 1 August 2015
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 365 (1) , 30-36
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- The distinctive nature of HER2-positive gastric cancersEuropean Journal of Surgical Oncology, 2015
- Review article: the epidemiology and prevention of gastric cancerAlimentary Pharmacology & Therapeutics, 2014
- c-Met as a Prognostic Marker in Gastric Cancer: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Gene methylation in gastric cancerClinica Chimica Acta, 2013
- Molecular targeted agents for gastric and gastroesophageal junction cancerSurgery Today, 2011
- A systematic review of surgery for non-curative gastric cancerGastric Cancer, 2011
- Anti-HER agents in gastric cancer: from bench to bedsideNature Reviews Gastroenterology & Hepatology, 2011
- New targeted therapies for gastric cancerExpert Opinion on Investigational Drugs, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Epigenetics in Gastric Cancer: Challenges for Clinical ImplicationsAnnals of Surgical Oncology, 2009